Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director Bell Potter Life Sciences Conference Investor Presentation May 2012
Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States’ Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics’ development candidates BNC105, BNC210, its Merck Serono alliance, its licensing agreement with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. 2
Bionomics: Key Facts 2 YEAR SHARE PRI CE PERFORMANCE KEY STATI STI CS ( 2 1 .5 .1 2 ) $0.80 30m ASX Code BNO $0.70 25m Current Share Price A$ 0 .3 4 $0.60 20m 5 2 W eek High A$ 0 .7 7 $0.50 15m 5 2 W eek Low A$ 0 .3 1 $0.40 10m Shares on I ssue 3 4 5 .3 m $0.30 5m Market Capitalisation A$ 1 1 8 m $0.20 0 May 10 Nov 10 May 11 Nov 11 Net Cash ( 3 1 .3 .1 1 ) A$ 1 8 .8 m Bionomics Ltd. (ASX:BNO) - Volume Bionomics Ltd. (ASX:BNO) - Share Pricing BOARD AND MANAGEMENT MAJOR SHAREHOLDERS Chris Fullerton Chairm an Link Traders 1 1 % Deborah Rathjen CEO & MD Ausbil Dexia 7 % Errol De Souza Non-Exec Director Australian National Trevor Tappenden Non-Exec Director 7 % University Em ile Andriam beloson Head of Research Neurofit TOP 2 0 HOLDERS ~ 5 0 % Andrew Harvey VP Drug Discovery Gabriel Krem m idiotis VP R&D Melanie Young CFO 3
Business Model: Targeting Significant Markets Developer of innovative small molecule pharmaceuticals with “blockbuster” � potential Target large markets: � Cancer ( solid tum ours) >US$10 billion p.a. � Central Nervous System ( CNS) ≈ US$75 billion p.a. � I m m une Diseases >US$46 billion p.a. � The leading drug candidates within a deep portfolio are: � � BNC1 0 5 : � All solid cancer tumours � Phase II trials targeting renal & ovarian cancers � BNC2 1 0 : � Anxiety and depression � Recently licenced to Ironwood Pharmaceuticals (IRWD:US) � US$345 million in pre-commercial payments � Including anticipated US$13 million to January 2014 � Plus royalty on product sales 4
Bionomics: Broad Product Pipeline PRE- LI CENSEE/ DRUG CANDI DATE/ PROGRAM DI SCOVERY PHASE I PHASE I I CLI NI CAL PARTNER BNC2 1 0 – Anxiety/Depression CENTRAL Alpha 7 – Alzheimer's Disease, ADHD, NERVOUS schizophrenia SYSTEM GABA-A – Epilepsy BNC1 0 5 – Renal cancer BNC1 0 5 - Mesothelioma BNC1 0 5 – Ovarian CANCER Undisclosed Kinase BNO6 9 I MMUNE Kv1 .3 – Multiple Sclerosis, Rheumatoid Arthritis, DI SEASE Psoriasis Key Compound Early Stage Compound 5
BNC210: Partnered with Ironwood Pharmaceuticals The I ronw ood BNC2 1 0 Partnership: Up to US$345 million in upfront, development (clinical trials) and regulatory � milestone payments (i.e. all milestone payments are pre-sales). Royalty on net sales of products incorporating BNC210. � US$13 million anticipated to January 2014. � Ironwood will fund all clinical trials and other development activities. � About I ronw ood: Specialty pharmaceutical company based in Cambridge, Massachusetts with � market capitalisation of US$1.54 Billion. (NASDAQ:IRWD) Extensive clinical trial expertise with IBS drug linaclotide, currently under review � by both the FDA (September 2012 PDUFA) and the EMA. Linaclotide met all 66 US and EU primary & secondary endpoints in four Phase 3 � trials. 6
BNC210: Fewer side-effects expected to be a key product differentiator COMPETI TI VE ADVANTAGES OF BNC2 1 0 * NO ONCE-A- NO NO MEMORY FAST NO DRUG/ DRUG DRUG W I THDRAW AL DAY SEDATI ON I MPAI RMENT ACTI NG I NTERACTI ONS SYNDROME DOSI NG � � � � � � BNC2 1 0 � � � � � � VALI UM � � � � � � PROZAC � � � � � � BUSPAR * Based on preclinical data and results of Phase Ib trial comparing BNC210 with Lorazepam 7
BNC210 (IW-2143): Progressing rapidly within Ironwood Current activities directed towards: � Increasing understanding of biology � Undertaking formulation development � Additional manufacture � Advancing IND � Initiating Phase Ib and planning for Phase IIa � Expanding the preclinical safety program to enable later stage trials � Initial focus: driving to human proof of concept in anxiety 8
BNC105: “Best in Class” Vascular Disrupting Agent TREATMENT Solid Cancers Proprietary, novel vascular disruption agent (VDA) � MODE OF Rapidly shuts down existing & new tumour blood vessels � ACTI ON No impact on normal blood vessels � Dual Action – selectively targets both tumour blood vessels � and cancer cells, potent action as a single agent Highly Effective – works rapidly to shut down tumour blood � vessels, tumour less likely to escape treatment BENEFI TS Enhances Effectiveness of Other Cancer Treatm ents – � delivers synergistic anti-cancer effects in numerous combinations The current market size in treatment of all solid tumours is � MARKETS >US$10b (Avastin, Genentech/Roche sales >US$5b in 2011) 9
BNC105: Targeting Solid Tumours By selectively shutting dow n tum our blood vessels, BNC1 0 5 rapidly inhibits tum our grow th BNC1 0 5 untreated treated 10
BNC105: Multiple Cancer Targets Phase I I Trial Program � Renal cancer ( US) Market size >US$2.5bn � Sutent, Pfizer ; Nexavar, Bayer/ Onyx; Afinitor, Novartis � Afinitor combination has potential to extend to breast cancer and pancreatic � tumours, for example � Ovarian cancer ( Australia, New Zealand, US) Trial approved, anticipated to launch Q2, CY2012 � Market size ≈ US$2.2bn in 2011 � Carboplatin, BMS ; Gemcitabine, Eli Lilly � Drug combination has potential to extend to lung, prostate and breast � cancer, for example � Mesotheliom a ( Australia) Currently investigating a trial involving combination with Alimta ( Eli Lilly) � and cisplatin ( Pfizer, Teva, Hospira & others) 11
BNC105: Renal Cancer Right Kidney Tum our Burden Potential to be a new � treatment paradigm for patients with renal cancer Encouraging initial results � from US renal cancer trial � Combination of Afinitor & BNC105 safe & well tolerated As effective as Sutent in � reducing tumour size in animal model � Sutent ( Pfizer ) is the current market leader with Globally, Renal Cancer is 7 th 2010 global sales US$1b most common form of cancer resulting in over 100,000 deaths p.a. 12
BNC105: Ovarian cancer Ovarian cancer is 5 th leading cause of cancer-related death am ong w om en. I n the US Ovarian Cancer is responsible for: � 2 1 ,8 8 0 new cases & 1 3 ,8 5 0 deaths ( 2 0 1 0 ) � ~ $ 2 .2 b pa spent in treatm ent. BNC105 preclinical data � supports ovarian cancer trial: 100 � Potent cytotoxic for platin 80 Percent survival sensitive and resistant ovarian cancer cells 60 � Inhibits tumour growth and 40 improves survival in cisplatin-resistant ovarian 20 cancer model 0 � Treatm ent of lung 0 10 20 30 40 50 60 cancer-bearing anim als Day w ith BNC1 0 5 + cisplatin Vehicle Cisplatin BNC105P BNC105P + Cisplatin results in 1 0 0 % survival 13
Recommend
More recommend
